Newsletter | June 12, 2026

06.12.26 -- Why Cell And Gene Therapy Has Not Reached More Patients — And Why Clinical Operations Is The Bridge

FOCUS ON SUPPLY CHAIN

Leveraging Single-Use Solutions To Solve Working Cell Bank Challenges

Discover how custom manifolds enhance allogeneic therapy development from formulation to commercialization by improving process control, scalability, and efficiency.

New Containers To Protect Bulk Frozen Biopharmaceuticals

Explore these new flexible freeze containers that maintain package integrity after freezing at -86 °C (-123 °F) through their durable design, minimizing product loss and package failure.

FOCUS ON CLINICAL TRIALS

Why Cell And Gene Therapy Has Not Reached More Patients And Why Clinical Operations Is The Bridge

Cell and gene therapy (CGT) has already changed oncology and rare disease care. The next challenge is translating scientific possibilities into credible evidence — and translating approved therapies into financially sustainable patient access.

Early Phase Oncology Site Network: Benefits Of A Personal Touch

Choose a site network built on partnership — not volume — to drive smoother early-phase oncology trials and deliver better outcomes for sponsors, sites, and patients.

Guiding GLP-1 Participants Through The Challenge Of Retention

Learn how remote lifestyle coaching can combat high dropout rates in metabolic research by offering the support participants need to maintain adherence and ensure data integrity.

From Bench To Approval: Smart IVBE Strategies For Complex Drugs

In vitro bioequivalence can replace clinical studies for complex products when well designed. Clinically relevant, risk-based methods under realistic conditions show site-of-action equivalence.

CLINICAL TRIALS SOLUTIONS

Connecting Manufacturers And Providers To The Services Needed For Full End-To-End Patient And Order Management - Cencora

Connect With Cell & Gene: